Thinking of joining a study?

Register your interest

NCT04587323 | RECRUITING | COVID-19 Disease


VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
Sponsor:

University of Alabama at Birmingham

Information provided by (Responsible Party):

Dylan R. Addis, MD

Brief Summary:

To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.

Condition or disease

COVID-19 Disease

Detailed Description:

When patients are sick with other lung infections (pneumonias) caused by viruses or bacteria there are changes in a pathway that regulates the "leakiness" the tiny airspaces inside the lungs. Even bigger changes in this pathway are seen when patients develop severe breathing difficulties (acute respiratory distress syndrome) similar to what is seen in patients who get really sick with COVID-19 disease. There are important changes in this pathway that occur in patients who have preexisting cardiovascular (heart) disease who do not have lung infections. The investigator will evaluate these levels in patients with COVID-19 because the investigator believes that this baseline difference in pathway regulation may be one reason patients with heart disease who contract COVID-19 get sicker than patients without heart or vascular disease. The investigator will also assess the levels of components of this pathway in patients who are less sick with those who became sick enough to require a tube to help them breathe because this is important to determine if COVID-19 lung disease has a similar effect on this pathway as other lung infections like flu and bacterial pneumonias.

Study Type : OBSERVATIONAL
Estimated Enrollment : 100 participants
Official Title : COVID-19 RELATED SUBMISSION: VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
Actual Study Start Date : 2020-05-22
Estimated Primary Completion Date : 2025-12-20
Estimated Study Completion Date : 2026-12-20

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Positive test for COVID-19 (SARS-CoV-2 infection)
  • * \>=18 years
  • * Blood (plasma) specimen(s) available in the CCTS biorepository
Exclusion Criteria
  • * \<18 years
  • * Lack of blood specimen

VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

Location Details

NCT04587323


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

United States, Albama

University of Alabama at Birmingham

Birmingham, Albama, United States, 35294

Loading...